Elevance Health, Inc. (ELV)
(Delayed Data from NYSE)
$544.63 USD
-1.33 (-0.24%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $544.62 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$544.63 USD
-1.33 (-0.24%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $544.62 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
Zacks News
Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and Genmab AS Sponsored ADR (GMAB) have performed compared to their sector so far this year.
Why You Should Add UnitedHealth (UNH) to Your Portfolio Now
by Zacks Equity Research
The improvement of the economy is likely to support UnitedHealth's (UNH) commercial business recovery.
Centene (CNC) to Sell Magellan Arm, To Use Proceeds for Buybacks
by Zacks Equity Research
Centene (CNC) strikes a deal with Evolent to divest Magellan Specialty Health, a Magellan Health arm, to deepen focus on solidifying its core Managed Care business.
Why Is Elevance Health (ELV) Down 5% Since Last Earnings Report?
by Zacks Equity Research
Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teladoc (TDOC) Achieves Momentous 50M Milestone in Visits
by Zacks Equity Research
Of the 50 million visits to Teladoc (TDOC), around one-third took place in the last year alone.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
3 Reasons Growth Investors Will Love Elevance Health (ELV)
by Zacks Equity Research
Elevance Health (ELV) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ELV or PGNY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. PGNY: Which Stock Is the Better Value Option?
Select Medical (SEM) Shares Fall 9.6% Since Q3 Earnings Miss
by Zacks Equity Research
Select Medical (SEM) reports improved performance in the Rehabilitation Hospital unit for the third quarter.
Why Is Encompass Health (EHC) Up 7.5% Despite Q3 Earnings Miss?
by Zacks Equity Research
Encompass Health (EHC) intends to open 6-10 de novo locations and increase the bed count by 100-150 per annum, till 2026.
Teladoc (TDOC) Up 1.6% Since Q3 Earnings Beat on Higher Visits
by Zacks Equity Research
Teladoc (TDOC) projects total visits in the band of 18.4-18.6 million for 2022.
PerkinElmer (PKI) Q3 Earnings Top, Revenues Decline Y/Y
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results benefit from the solid performance of the Discover & Analytics Solutions business, which was more than offset by lower COVID-related sales.
Shockwave Medical (SWAV) Beats on Q3 Earnings & Revenues
by Zacks Equity Research
Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and expansion in gross margin.
Why Is Community Health (CYH) Up 27.8% Despite Q3 Earnings Miss?
by Zacks Equity Research
Community Health (CYH) expects labor inflation for 2023 to be within the 3-4% range.
Cardinal Health (CAH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal first-quarter results benefit from the solid performance of the Pharmaceutical segment.
Exact Sciences (EXAS) Q3 Earnings Top Estimates, Margin Falls
by Zacks Equity Research
Exact Sciences (EXAS) registers robust revenues from the Screening and Precision Oncology segments in Q3.
Illumina (ILMN) Q3 Earnings Beat Estimates, '22 View Slashed
by Zacks Equity Research
Delays in instruments and consumables purchases, negative foreign exchange impact and consumables inventory deleveraging are expected to impede growth in the rest of 2022 for Illumina (ILMN).
AMN Healthcare (AMN) Q3 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q3 results demonstrate its segmental strength.
Accuray's (ARAY) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Despite solid product demand, Accuray (ARAY) reports an overall soft Q1 performance.
Myriad Genetics (MYGN) Q3 Earnings Miss, Gross Margin Falls
by Zacks Equity Research
Myriad Genetics (MYGN) hereditary cancer testing volume returns to growth in the third quarter. GeneSight comes up with yet another strong performance.
AmerisourceBergen (ABC) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter 2022 results benefit from segmental growth.
LHC Group's (LHCG) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
LHC Group's (LHCG) third-quarter results benefit from organic growth in hospice admissions. However, home health admissions decline organically.
Chemed (CHE) Q3 Earnings Surpass Estimates, EPS View Up
by Zacks Equity Research
Chemed's (CHE) full-year VITAS revenues, prior to Medicare Cap, are once again estimated to decline.
Inari Medical (NARI) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Inari Medical's (NARI) third-quarter results benefit from significant progress made across all its growth drivers.
Inogen (INGN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inogen's (INGN) third-quarter results benefit from higher revenues in its domestic business-to-business sales channel.